Join        Login             Stock Quote

Goldman Sachs (GS) Raises PT On Edwards Lifesciences (EW) To $97, Reiterates 'CL-Buy'

 May 02, 2012 10:18 AM

(By Balachander) Goldman Sachs (GS) raised its price target on shares of Edwards Lifesciences Corp. (NYSE:EW) to $97 from $90, while reiterating its "Conviction List-Buy" rating on the stock.

On May 1, the Centers for Medicare and Medicaid Services (CMS) released the final Medicare National Coverage Determination (NCD) document for transcatheter aortic valve replacement (TAVR) procedures.

"After a detailed review of the CMS documents as well as physician and industry participant conversations, we remain confident in our launch assumptions for the company's SAPIEN TAVR in the US, and maintain our estimates," GS analyst David Roman wrote.

[Related -Gold hasn’t lost its allure in my portfolio]

"Looking specifically at the NCD, we think the CMS requirements for centers and physicians to receive TAVR reimbursement appear achievable for about one third of cardiac surgery centers in the US, or roughly 400 centers (this supports our 2015E above-consensus numbers at current per center utilization rates)," the analyst said.

Now that the guidelines have been issued, Roman thinks the ramp in center opening should accelerate (Edwards had trained 60 centers as of March 31, 2012). "Feedback from the American College of Cardiology meeting and our March physician survey indicates that once physicians are trained, procedure volumes ramp at a steadily increasing rate," the analyst said.

[Related -Should You Buy HP's Stellar Rebound?]

Beyond the facility requirements, CMS removed a potentially arduous component of the proposed NCD related to clinical trial design that could have reduced Edwards' annual EPS by $0.25 (9 percent - 10 percent of 2012E), by Roman's estimates.

Irvine, California-based Edwards Lifesciences provides heart valve therapy products, including tissue heart valves and repair products. The company also offers critical care products comprising hemodynamic monitoring systems.

The stock, which has been trading in the 52-week range between $61.59 and $91.50, added 80 cents to trade at $85.58.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageFour Stocks in the Dow Making Fresh 52 Week Lows

“What gets weak tends to get weaker; what gets strong tends to get read on...

article imageGreece And The Cemetery For Your Wealth

The Greek default is merely the opening act of the worst sovereign-debt crisis in history. By the time it read on...

article imageAll Signs Point To Higher Gold Prices

In the face of historic monetary stimulus from nearly every major central bank in the world over the past read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Melt Up Or Melt Down?
More Articles on: Finance , Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.